Markowski, M. C., Frick, K. D., Eshleman, J. R., Luo, J., & Antonarakis, E. S. (2016). Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate.
Citação norma ChicagoMarkowski, Mark C., Kevin D. Frick, James R. Eshleman, Jun Luo, e Emmanuel S. Antonarakis. "Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide." Prostate 2016.
Citação norma MLAMarkowski, Mark C., et al. "Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide." Prostate 2016.